Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin

Journal of Pineal Research

Volumn 61, Issue 4, 2016, Pages 411-425

  Hosseinzadeh, Azam ^a   Kamrava, Seyed Kamran ^b   Joghataei, Mohammad Taghi ^c   Darabi, Radbod ^d   Shakeri Zadeh, Ali ^a   Shahriari, Mansour ^e   Reiter, Russel J ^f   Ghaznavi, Habib ^g   Mehrzadi, Saeed ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f Mays Cancer Center at UT Health San Antonio   (United States)

^g ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

apoptosis; endoplasmic reticulum; inflammation; melatonin; mitochondria; molecular actions; osteoarthritis; oxidative stress

Indexed keywords

ARACHIDONIC ACID; INTERLEUKIN 1BETA; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR; IL1B PROTEIN, HUMAN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CARTILAGE CELL; CARTILAGE DEGENERATION; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMAN; MITOCHONDRION; OSTEOARTHRITIS; OXIDATIVE STRESS; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHONDROCYTE; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; CHONDROCYTES; ENDOPLASMIC RETICULUM STRESS; HUMANS; INTERLEUKIN-1BETA; MELATONIN; OSTEOARTHRITIS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84988867428     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12362     Document Type: Review

References (221)

1. Loza E, Lopez-Gomez JM, Abasolo L, et al. Economic burden of knee and hip osteoarthritis in Spain. Arthritis Rheum. 2009;61:158–165.
2. Spector TD. Epidemiology of the rheumatic diseases. Curr Opin Rheumatol. 1993;5:132–137.
3. Nakata K, Ono K, Miyazaki J, et al. Osteoarthritis associated with mild chondrodysplasia in transgenic mice expressing alpha 1 (IX) collagen chains with a central deletion. Proc Natl Acad Sci USA. 1993;90:2870–2874.
4. Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res. 2001;3:107–113.
5. Im HJ, Li X, Muddasani P, et al. Basic fibroblast growth factor accelerates matrix degradation via a neuro-endocrine pathway in human adult articular chondrocytes. J Cell Physiol. 2008;215:452–463.
6. Bauer DC, Hunter DJ, Abramson SB, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthr Cartil. 2006;14:723–727.
7. Lane NE, Brandt K, Hawker G, et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthr Cartil. 2011;19:478–482.
8. Reiter RJ. Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals. Eur J Endocrinol. 1996;134:412–420.
9. Manchester LC, Coto-Montes A, Boga JA, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403–419.
10. Reiter RJ, Mayo JC, Tan DX, et al. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res 2016;1–26; in press.
11. Khaksary Mahabady MK, Najafzadeh Varzi H, Ranjbar R, et al. Melatonin and vitamin E protects against sodium arsenite-induced skeletal malformations in rats. Am Eurasian J Toxicol Sci. 2011;3:184–189.
12. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physiochemical examination. J Pineal Res. 2011;51:1–16.
13. Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res. 2013;54:245–257.
14. Allegra M, Reiter RJ, Tan DX, et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res. 2003;34:1–10.
15. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1–9.
16. Mehrzadi S, Kamrava SK, Dormanesh B, et al. Melatonin synergistically enhances protective effect of atorvastatin against gentamicin-induced nephrotoxicity in rat kidney. Can J Physiol Pharmacol. 2016;94:265–271.
17. Ghaznavi H, Mehrzadi S, Dormanesh B, et al. Comparison of the protective effects of melatonin and silymarin against gentamicin-induced nephrotoxicity in rats. J Evid Based Complementary Altern Med. 2015;1–7; in press.
18. Carrillo-Vico A, Reiter RJ, Lardone PJ, et al. The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs. 2006;7:423–431.
19. Lee SJ, Jung YH, Oh SY, et al. Melatonin enhances the human mesenchymal stem cells mobility via melatonin receptor 2 coupling with Gαq in skin wound healing. J Pineal Res. 2014;57:393–407.
20. Gögenur I, Kücükakin B, Panduro Jensen L, et al. Melatonin reduces cardiac morbidity and markers of myocardial ischemia after elective abdominal aortic aneurism repair: a randomized, placebo-controlled, clinical trial. J Pineal Res. 2014;57:10–15.
21. Wei JY, Li WM, Zhou LL, et al. Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear impact mediated by CaMk11 inactivation. J Pineal Res. 2015;58:429–438.
22. Borin TF, Arbab AS, Gelaleti GB, et al. Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression. J Pineal Res. 2016;60:3–15.
23. Greenwald RA. Oxygen radicals, inflammation, and arthritis: pathophysiological considerations and implications for treatment. Semin Arthritis Rheum. 1991;20:219–240.
24. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthr Cartil. 2003;11:747–755.
25. Martin JA, Brown T, Heiner A, et al. Post-traumatic osteoarthritis: the role of accelerated chondrocyte senescence. Biorheology. 2004;41:479–492.
26. Martin JA, Brown TD, Heiner AD, et al. Chondrocyte senescence, joint loading and osteoarthritis. Clin Orthop Relat Res. 2004;427:S96–S103.
27. Dimock AN, Siciliano PD, McIlwraith CW. Evidence supporting an increased presence of reactive oxygen species in the diseased equine joint. Equine Vet J. 2000;32:439–443.
28. Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res. 2004;427:S37–S46.
29. Haklar U, Yüksel M, Velioglu A, et al. Oxygen radicals and nitric oxide levels in chondral or meniscal lesions or both. Clin Orthop Relat Res. 2002;403:135–142.
30. Im HJ, Muddasani P, Natarajan V, et al. Basic fibroblast growth factor stimulates matrix metalloproteinase-13 via the molecular cross-talk between the mitogen-activated protein kinases and protein kinase Cδ pathways in human adult articular chondrocytes. J Biol Chem. 2007;282:11110–11121.
31. Kawai Y, Kubota E, Okabe E. Reactive oxygen species participation in experimentally induced arthritis of the temporomandibular joint in rats. J Dent Res. 2000;79:1489–1495.
32. Ostalowska A, Birkner E, Wiecha M, et al. Lipid peroxidation and antioxidant enzymes in synovial fluid of patients with primary and secondary osteoarthritis of the knee joint. Osteoarthr Cartil. 2006;14:139–145.
33. Martin JA, Klingelhutz AJ, Moussavi-Harami F, et al. Effects of oxidative damage and telomerase activity on human articular cartilage chondrocyte senescence. J Gerontol A Biol Sci Med Sci. 2004;59:324–336.
34. Lee SH, Chang DK, Goel A, et al. Microsatellite instability and suppressed DNA repair enzyme expression in rheumatoid arthritis. J Immunol. 2003;170:2214–2220.
35. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552:335–344.
36. Ghaznavi H, Najafi R, Mehrzadi S, et al. Neuro-protective effects of cerium and yttrium oxide nanoparticles on high glucose-induced oxidative stress and apoptosis in undifferentiated PC12 cells. Neurol Res. 2015;37:624–632.
37. Da Sylva TR, Connor A, Mburu Y, et al. Somatic mutations in the mitochondria of rheumatoid arthritis synoviocytes. Arthritis Res Ther. 2005;7:R844–R851.
38. Grishko VI, Ho R, Wilson GL, et al. Diminished mitochondrial DNA integrity and repair capacity in OA chondrocytes. Osteoarthr Cartil. 2009;17:107–113.
39. Ospelt C, Gay S. Somatic mutations in mitochondria: the chicken or the egg? Arthritis Res Ther. 2005;7:179.
40. Blanco FJ, Rego I, Ruiz-Romero C. The role of mitochondria in osteoarthritis. Nat Rev Rheumatol. 2011;7:161–169.
41. Johnson K, Svensson CI, Etten DV, et al. Mediation of spontaneous knee osteoarthritis by progressive chondrocyte ATP depletion in Hartley guinea pigs. Arthritis Rheum. 2004;50:1216–1225.
42. Liu JT, Guo X, Ma WJ, et al. Mitochondrial function is altered in articular chondrocytes of an endemic osteoarthritis, Kashin-Beck disease. Osteoarthr Cartil. 2010;18:1218–1226.
43. Maneiro E, Martín MA, de Andres MC, et al. Mitochondrial respiratory activity is altered in osteoarthritic human articular chondrocytes. Arthritis Rheum. 2003;48:700–708.
44. Roach HI. The complex pathology of osteoarthritis: even mitochondria are involved. Arthritis Rheum. 2008;58:2217–2218.
45. Terkeltaub R, Johnson K, Murphy A, et al. Invited review: the mitochondrion in osteoarthritis. Mitochondrion. 2002;1:301–319.
46. Sowers M. Epidemiology of risk factors for osteoarthritis: systemic factors. Curr Opin Rheumatol. 2001;13:447–451.
47. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81–128.
48. Roberts LJ, Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta. 1997;1345:121–135.
49. Basu S, Whiteman M, Mattey DL, et al. Raised levels of F2-isoprostanes and prostaglandin F2α in different rheumatic diseases. Ann Rheum Dis. 2001;60:627–631.
50. Lippiello L, Walsh T, Fienhold M. The association of lipid abnormalities with tissue pathology in human osteoarthritic articular cartilage. Metabolism. 1991;40:571–576.
51. Tiku ML, Gupta S, Deshmukh DR. Aggrecan degradation in chondrocytes is mediated by reactive oxygen species and protected by antioxidants. Free Radic Res. 1999;30:395–405.
52. Tiku ML, Yan YP, Chen KY. Hydroxyl radical formation in chondrocytes and cartilage as detected by electron paramagnetic resonance spectroscopy using spin trapping reagents. Free Radic Res. 1998;29:177–187.
53. Martel-Pelletier J, Lajeunesse D, Reboul P, et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2003;62:501–509.
54. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871–1875.
55. Fulkerson JP, Damiano P. Effect of prostaglandin E2 on adult pig articular cartilage slices in culture. Clin Orthop Relat Res. 1983;179:266–269.
56. Hardy MM, Seibert K, Manning PT, et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum. 2002;46:1789–1803.
57. Shapiro SD, Kobayashi DK, Pentland AP, et al. Induction of macrophage metalloproteinases by extracellular matrix. Evidence for enzyme-and substrate-specific responses involving prostaglandin-dependent mechanisms. J Biol Chem. 1993;268:8170–8175.
58. Studer R, Jaffurs D, Stefanovic-Racic M, et al. Nitric oxide in osteoarthritis. Osteoarthr Cartil. 1999;7:377–379.
59. Yamada H, Kikuchi T, Nemoto O, et al. Effects of indomethacin on the production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by human articular chondrocytes. J Rheumatol. 1996;23:1739–1743.
60. Bonizzi G, Piette J, Merville MP, et al. Cell type-specific role for reactive oxygen species in nuclear factor-kappaB activation by interleukin-1. Biochem Pharmacol. 2000;59:7–11.
61. Brigelius-Flohé R, Banning A, Kny M, et al. Redox events in interleukin-1 signaling. Arch Biochem Biophys. 2004;423:66–73.
62. Woo CH, Eom YW, Yoo MH, et al. Tumor necrosis factor-α generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. J Biol Chem. 2000;275:32357–32362.
63. Steiner DR, Gonzalez NC, Wood JG. Leukotriene B4 promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J Appl Physiol. 2001;91:1160–1167.
64. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635–646.
65. Felson DT, Lawrence RC, Hochberg MC, et al. Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med. 2000;133:726–737.
66. Hiran TS, Moulton PJ, Hancock JT. Detection of superoxide and NADPH oxidase in porcine articular chondrocytes. Free Radic Biol Med. 1997;23:736–743.
67. Rathakrishnan C, Tiku K, Raghavan A, et al. Release of oxygen radicals by articular chondrocytes: a study of luminol-dependent chemiluminescence and hydrogen peroxide secretion. J Bone Miner Res. 1992;7:1139–1148.
68. Lo YY, Cruz TF. Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. J Biol Chem. 1995;270:11727–11730.
69. Kurz B, Lemke A, Kehn M, et al. Influence of tissue maturation and antioxidants on the apoptotic response of articular cartilage after injurious compression. Arthritis Rheum. 2004;50:123–130.
70. Gutteridge JM, Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci. 1990;15:129–135.
71. Tiku ML, Liesch JB, Robertson FM. Production of hydrogen peroxide by rabbit articular chondrocytes. Enhancement by cytokines. J Immunol. 1990;145:690–696.
72. Bates EJ, Johnson CC, Lowther DA. Inhibition of proteoglycan synthesis by hydrogen peroxide in cultured bovine articular cartilage. Biochim Biophys Acta. 1985;838:221–228.
73. Asada S, Fukuda K, Nishisaka F, et al. Hydrogen peroxide induces apoptosis of chondrocytes; involvement of calcium ion and extracellular signal-regulated protein kinase. Inflamm Res. 2001;50:19–23.
74. Tiku ML, Shah R, Allison GT. Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation possible role in cartilage aging and the pathogenesis of osteoarthritis. J Biol Chem. 2000;275:20069–20076.
75. Jacques C, Gosset M, Berenbaum F, et al. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm. 2006;74:371–403.
76. Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol. 1998;10:263–268.
77. Abramson SB. Osteoarthritis and nitric oxide. Osteoarthr Cartil. 2008;16:S15–S20.
78. Pelletier JP, Mineau F, Ranger P, et al. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthr Cartil. 1996;4:77–84.
79. Blanco FJ, Ochs RL, Schwarz H, et al. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol. 1995;146:75.
80. Salvemini D, Misko TP, Masferrer JL, et al. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA. 1993;90:7240–7244.
81. Sasaki K, Hattori T, Fujisawa T, et al. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem. 1998;123:431–439.
82. Nakagawa S, Arai Y, Mazda O, et al. N-acetylcysteine prevents nitric oxide-induced chondrocyte apoptosis and cartilage degeneration in an experimental model of osteoarthritis. J Orthop Res. 2010;28:156–163.
83. Chevalier X, Conrozier T, Richette P. Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy. Arthritis Res Ther. 2011;13:124.
84. López-Armada MJ, Caramés B, Lires-Deán M, et al. Cytokines, tumor necrosis factor-α and interleukin-1β, differentially regulate apoptosis in osteoarthritis cultured human chondrocytes. Osteoarthr Cartil. 2006;14:660–669.
85. Dunn E, Sims JE, Nicklin MJ, et al. Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol. 2001;22:533–536.
86. Pizarro TT, Cominelli F. Cloning IL-1 and the birth of a new era in cytokine biology. J Immunol. 2007;178:5411–5412.
87. Sims JE, Pan Y, Smith DE, et al. A new nomenclature for IL-1-family genes. Trends Immunol. 2001;22:536.
88. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol. 1998;16:457–499.
89. Palmer G, Guerne PA, Mezin F, et al. Production of interleukin-1 receptor antagonist by human articular chondrocytes. Arthritis Res. 2002;4:226–231.
90. Seitz M, Loetscher P, Dewald B, et al. Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytes–regulation by IFN-gamma and IL-4. J Immunol. 1994;152:2060–2065.
91. Smith MD, Triantafillou S, Parker A, et al. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol. 1997;24:365–371.
92. Kubota E, Imamura H, Kubota T, et al. Interleukin 1β and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg. 1997;55:20–27.
93. Loeser RF, Carlson CS, Del Carlo M, et al. Detection of nitrotyrosine in aging and osteoarthritic cartilage: correlation of oxidative damage with the presence of interleukin-1β and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum. 2002;46:2349–2357.
94. Pelletier JP, McCollum R, Cloutier JM, et al. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J Rheumatol Suppl. 1995;43:109–114.
95. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3:cm1.
96. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6:232–241.
97. Boraschi D, Bossu P, Macchia G, et al. Structure-function relationship in the IL-1 family. Front Biosci. 1996;1:d270–d308.
98. Shlopov BV, Gumanovskaya ML, Hasty KA. Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis. Arthritis Rheum. 2000;43:195–205.
99. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 1993;9:317–343.
100. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372–377.
101. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65.
102. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–756.
103. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239–252.
104. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;23:2838–2849.
105. Tang RX, Kong FY, Fan BF, et al. HBx activates FasL and mediates HepG2 cell apoptosis through MLK3-MKK7-JNKs signal module. World J Gastroenterol. 2012;18:1485–1495.
106. Shajahan AN, Dobbin ZC, Hickman FE, et al. Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). J Biol Chem. 2012;287:17682–17692.
107. Hill MM, Adrain C, Duriez PJ, et al. Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. EMBO J. 2004;23:2134–2145.
108. Valladares A, Alvarez AM, Ventura JJ, et al. P38 Mitogen-activated protein kinase mediates tumor necrosis factor-α-induced apoptosis in rat fetal brown adipocytes 1. Endocrinology. 2000;141:4383–4395.
109. Edlund S, Bu S, Schuster N, et al. Transforming growth factor-β1 (TGF-β)–induced apoptosis of prostate cancer cells involves Smad7-dependent Activation of p38 by TGF-β-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell. 2003;14:529–544.
110. Zhuang S, Demirs JT, Kochevar IE. P38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide. J Biol Chem. 2000;275:25939–25948.
111. Schrantz N, Bourgeade MF, Mouhamad S, et al. P38-mediated regulation of an Fas-associated death domain protein-independent pathway leading to caspase-8 activation during TGFβ-induced apoptosis in human Burkitt lymphoma B cells BL41. Mol Biol Cell. 2001;12:3139–3151.
112. Sarkar D, Su ZZ, Lebedeva IV, et al. Mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA. 2002;99:10054–10059.
113. Lin T, Mak NK, Yang MS. MAPK regulate p53-dependent cell death induced by benzo [a] pyrene: involvement of p53 phosphorylation and acetylation. Toxicology. 2008;247:145–153.
114. Clancy R, Rediske J, Koehne C, et al. Activation of stress-activated protein kinase in osteoarthritic cartilage: evidence for nitric oxide dependence. Osteoarthr Cartil. 2001;9:294–299.
115. Fan Z, Söder S, Oehler S, et al. Activation of interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage. Am J Pathol. 2007;171:938–946.
116. Mengshol JA, Vincenti MP, Coon CI, et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-jun N-terminal kinase, and nuclear factor κB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000;43:801–811.
117. Liacini A, Sylvester J, Li WQ, et al. Induction of matrix metalloproteinase-13 gene expression by TNF-α is mediated by MAP kinases, AP-1, and NF-κB transcription factors in articular chondrocytes. Exp Cell Res. 2003;288:208–217.
118. Kumar S, Votta BJ, Rieman DJ, et al. IL-1-and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol. 2001;187:294–303.
119. Brown KK, Heitmeyer SA, Hookfin EB, et al. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008;5:22.
120. Pelletier JP, Fernandes JC, Jovanovic DV, et al. Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase. J Rheumatol. 2001;28:2509–2519.
121. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626–629.
122. Greenn DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309.
123. Reynafarje BD, Ferreira J. Oxidative phosphorylation: kinetic and thermodynamic correlation between electron flow, proton translocation, oxygen consumption and ATP synthesis under close to in vivo concentrations of oxygen. Int J Med Sci. 2008;5:143–151.
124. Mazat JP, Ransac S, Heiske M, et al. Mitochondrial energetic metabolism – some general principles. IUBMB Life. 2013;65:171–179.
125. Kienhöfer J, Häussler DJ, Ruckelshausen F, et al. Association of mitochondrial antioxidant enzymes with mitochondrial DNA as integral nucleoid constituents. FASEB J. 2009;23:2034–2044.
126. Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8:18–30.
127. Urban J. Evidence for a negative Pasteur effect in articular cartilage. Biochem J. 1997;321:95–102.
128. Reed KN, Wilson G, Pearsall A, et al. The role of mitochondrial reactive oxygen species in cartilage matrix destruction. Mol Cell Biochem. 2014;397:195–201.
129. Gardner BM, Walter P. Unfolded proteins are Ire1-activating ligands that directly induce the unfolded protein response. Science. 2011;333:1891–1894.
130. Hamamura K, Goldring MB, Yokota H. Involvement of p38 MAPK in regulation of MMP13 mRNA in chondrocytes in response to surviving stress to endoplasmic reticulum. Arch Oral Biol. 2009;54:279–286.
131. Takada K, Hirose J, Senba K, et al. Enhanced apoptotic and reduced protective response in chondrocytes following endoplasmic reticulum stress in osteoarthritic cartilage. Int J Exp Pathol. 2011;92:232–242.
132. Breckenridge D, Germain M, Mathai JP, et al. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene. 2003;22:8608–8618.
133. Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173–194.
134. Ron D, Hubbard SR. How IRE1 reacts to ER stress. Cell. 2008;132:24–26.
135. Rao RV, Hermel E, Castro-Obregon S, et al. Coupling endoplasmic reticulum stress to the cell death program mechanism of caspase activation. J Biol Chem. 2001;276:33869–33874.
136. Cullinan SB, Diehl JA. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem. 2004;279:20108–20117.
137. Price J, Zaidi AK, Bohensky J, et al. Akt-1 mediates survival of chondrocytes from endoplasmic reticulum-induced stress. J Cell Physiol. 2010;222:502–508.
138. Rasheed Z, Haqqi TM. Endoplasmic reticulum stress induces the expression of COX-2 through activation of eIF2α, p38-MAPK and NF-κB in advanced glycation end products stimulated human chondrocytes. Biochim Biophys Acta. 2012;1823:2179–2189.
139. Yang L, Carlson SG, McBurney D, et al. Multiple signals induce endoplasmic reticulum stress in both primary and immortalized chondrocytes resulting in loss of differentiation, impaired cell growth, and apoptosis. J Biol Chem. 2005;280:31156–31165.
140. Uehara Y, Hirose J, Yamabe S, et al. Endoplasmic reticulum stress-induced apoptosis contributes to articular cartilage degeneration via C/EBP homologous protein. Osteoarthr Cartil. 2014;22:1007–1017.
141. Yamabe S, Hirose J, Uehara Y, et al. Intracellular accumulation of advanced glycation end products induces apoptosis via endoplasmic reticulum stress in chondrocytes. FEBS J. 2013;280:1617–1629.
142. Hughes S, Jagannath A, Hankins MW, et al. Photic regulation of clock systems. Methods Enzymol. 2015;552:125–143.
143. Venegas C, García JA, Escames G, et al. Extrapineal melatonin: analyses of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52:217–227.
144. Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation and potential functions. Cell Mol Life Sci. 2014;71:2997–3025.
145. Stehle JH, Saade A, Rawashdeh O, et al. A survey of molecular details in the human pineal gland in the light of phylogeny structure, function and chronobiological diseases. J Pineal Res. 2011;51:17–43.
146. Vaughan GM, Pelham RW, Pang SF, et al. Nocturnal elevation of plasma melatonin and urinary 5-hydroxyindoleacetic acid in young men: attempts at modification by brief changes in environmental lighting and sleep and by autonomic drugs. J Clin Endocrinol Metab. 1976;42:752–764.
147. Skinner DC, Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology. 1999;140:4399–4405.
148. Reiter RJ, Tan DX, Kim SJ, et al. Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. Brain Struct Funct. 2014;219:1873–1887.
149. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia. 1993;49:654–664.
150. Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res. 2010;181:127–151.
151. Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014;29:325–333.
152. Hu W, Ma Z, Jiang S, et al. Melatonin: the dawning of a treatment for fibrosis. J Pineal Res. 2016;60:121–131.
153. Krause DN, Dubocovich ML. Regulatory sites of the melatonin system of mammals. Trends Neurosci. 1990;13:464–470.
154. Maria S, Witt-Enderby PA. Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal diseases and for use in bone-grafting procedures. J Pineal Res. 2014;56:115–125.
155. Rawashdeh O, Dubocovich ML. Long-term effects of maternal separation on the responsiveness of the circadian system to melatonin in the diurnal nonhuman primate (Macaca mulatta). J Pineal Res. 2014;56:254–263.
156. Cipolla-Neto J, Amaral FG, Afech SC, et al. Melatonin energy metabolism, and obesity: a review. J Pineal Res. 2014;56:371–381.
157. Peschke E, Bahr I, Muhlbauer E. Experimental and clinical aspects of melatonin and clock genes in diabetes. J Pineal Res. 2015;58:1–23.
158. Miller E, Morel A, Saso L, et al. Melatonin redox activity: its potential clinical applications in neurodegenerative disorders. Curr Top Med Chem. 2015;15:163–169.
159. Vriend J, Reiter RJ. Melatonin feedback on clock genes: a theory involving the proteasome. J Pineal Res. 2015;58:1–11.
160. Sun CK, Lee FY, Kao YH, et al. Systemic combined melatonin-mitochondria treatment improves acute respiratory distress syndrome in the rat. J Pineal Res. 2015;58:137–150.
161. Xin Z, Jaing S, Yan X, et al. Melatonin as a treatment for gastrointestinal cancer: a review. J Pineal Res. 2015;58:375–387.
162. Tan DX, Manchester LC, Terron MP, et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species. J Pineal Res. 2007;42:28–42.
163. García JJ, López-Pingarrón L, Almeida-Souza P, et al. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res. 2014;56:225–237.
164. Romero A, Ramos E, de Los Ríos C, et al. A review of metal-catalyzed molecular damages: protection by melatonin. J Pineal Res. 2014;56:343–370.
165. Galano A, Medina ME, Tan DX, et al. Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physiochemical analysis. J Pineal Res. 2015;58:107–116.
166. Yeung HM, Hung MW, Lau CF. Cardioprotective effects of melatonin against myocardial injuries induced by intermittent hypoxia in rats. J Pineal Res. 2015;58:12–25.
167. Borges Lda S, Dermargos A, da Silva Junior EP, et al. Melatonin decreases muscular oxidative stress and inflammation induced by strenuous exercise and stimulates growth factor synthesis. J Pineal Res. 2015;58:166–172.
168. Hardeland R, Cardinali DP, Brown GM, et al. Melatonin and brain inflammaging. Prog Neurobiol. 2015;127–128:46–63.
169. Reiter RJ, Tan DX, Manchester LC, et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci. 2007;52:11–28.
170. Slominski AT, Kleszczyński K, Semak I, et al. Local melatoninergic system as a protector of skin integrity. Int J Mol Sci. 2014;15:17705–17732.
171. Boutin JA. Quinone reductase 2 as a promising target of melatonin therapeutic actions. Expert Opin Ther Targets. 2016;20:303–317.
172. Cruz MH, Leal CL, da Cruz JF, et al. Role of melatonin on production and preservation of gametes and embryos: a brief review. Anim Reprod Sci. 2014;145:150–160.
173. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidant enzymes. J Pineal Res. 2005;39:99–104.
174. Espino J, Ortiz Á, Bejarano I, et al. Melatonin protects human spermatozoa from apoptosis via melatonin receptor–and extracellular signal–regulated kinase-mediated pathways. Fertil Steril. 2011;95:2290–2296.
175. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634–1635.
176. Greenfeder SA, Nunes P, Kwee L, et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem. 1995;270:13757–13765.
177. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550.
178. Brikos C, Wait R, Begum S, et al. Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. Mol Cell Proteomics. 2007;6:1551–1559.
179. Li S, Strelow A, Fontana EJ, et al. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA. 2002;99:5567–5572.
180. Kawagoe T, Sato S, Matsushita K, et al. Sequential control of Toll-like receptor–dependent responses by IRAK1 and IRAK2. Nat Immunol. 2008;9:684–691.
181. Cao Z, Xiong J, Takeuchi M, et al. TRAF6 is a signal transducer for interleukin-1. Nature. 1996;383:443–446.
182. Cao Z, Henzel WJ, Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science. 1996;271:1128–1131.
183. Yamazaki K, Gohda J, Kanayama A, et al. Two mechanistically and temporally distinct NF-κB activation pathways in IL-1 signaling. Sci Signal. 2009;2:ra66.
184. Yao J, Kim TW, Qin J, et al. Interleukin-1 (IL-1)-induced TAK1-dependent versus MEKK3-dependent NFκB activation pathways bifurcate at IL-1 receptor-associated kinase modification. J Biol Chem. 2007;282:6075–6089.
185. Huang Q, Yang J, Lin Y, et al. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol. 2004;5:98–103.
186. Shim J-H, Xiao C, Paschal AE, et al. TAK1, but not TAB 1 or TAB 2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005;19:2668–2681.
187. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev. 2002;12:14–21.
188. Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta. 2007;1773:1341–1348.
189. Donovan N, Becker EB, Konishi Y, et al. JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem. 2002;277:40944–40949.
190. Putcha GV, Le S, Frank S, et al. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron. 2003;38:899–914.
191. Becker EB, Howell J, Kodama Y, et al. Characterization of the c-Jun N-terminal kinase-BimEL signaling pathway in neuronal apoptosis. J Neurosci. 2004;24:8762–8770.
192. Ley R, Ewings KE, Hadfield K, et al. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ. 2005;12:1008–1014.
193. Rodella LF, Favero G, Rossini C, et al. Aging and vascular dysfunction: beneficial melatonin effects. Age (Dordr). 2013;35:103–115.
194. Barlow-Walden LR, Reiter RJ, Abe M, et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int. 1995;26:497–502.
195. Pablos M, Agapito MT, Gutierrez R, et al. Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. J Pineal Res. 1995;19:111–115.
196. Reiter RJ, Tan DX, Maldonado MD. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res. 2005;39:215–216.
197. Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem. 2002;2:181–197.
198. Sewerynek E, Melchiorri D, Chen L, et al. Melatonin reduces both basal and lipopolysaccharide-induced lipid peroxidation in vitro. Free Radic Biol Med. 1995;19:903–909.
199. Lu T, Galijasevic S, Abdulhamid I, et al. Analysis of the mechanism by which melatonin inhibits human eosinophil peroxidase. Br J Pharmacol. 2008;154:1308–1317.
200. Urata Y, Honma S, Goto S, et al. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med. 1999;27:838–847.
201. Mayo JC, Sainz RM, Antolin I, et al. Melatonin regulation of antioxidant enzyme expression. Cell Mol Life Sci. 2002;59:1706–1713.
202. Vriend J, Reiter RJ. The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. Mol Cell Endocrinol. 2015;401:213–220.
203. Hardeland R, Cardinali DP, Srinivasan V, et al. Melatonin–a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93:350–384.
204. Benítez-King G, Huerto-Delgadillo L, Antón-Tay F. Bindings of 3H-melatonin to calmodulin. Life Sci. 1993;53:201–207.
205. Pozo D, Reiter RJ, Calvo JR, et al. Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci. 1994;5:PL455–PL460.
206. Pozo D, Reiter RJ, Calvo JR, et al. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation and calmodulin. J Cell Biochem. 1997;65:430–442.
207. Macías M, Escames G, Leon J, et al. Calreticulin-melatonin: an unexpected relationship. Eur J Biochem. 2003;270:832–840.
208. Benitez-King G, Túnez I, Bellon A, et al. Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in NIE-115 cells. Exp Neurol. 2003;182:151–159.
209. Jiménez-Rubio G, Ortíz-López L, Benítez-King G. Melatonin modulates cytoskeletal organization in the rat brain hippocampus. Neurosci Lett. 2012;51:47–51.
210. Acuña-Castroviejo D, Carretero M, Doerrier C, et al. Melatonin protects lung mitochondria from aging. Age (Dordr). 2012;34:681–692.
211. Acuna-Castroviejo D, Escames G, Rodriguez MI, et al. Melatonin role in the mitochondrial function. Front Biosci. 2007;12:947–963.
212. Lin AM, Fang SF, Chao PL, et al. Melatonin attenuates arsenite-induced apoptosis in rat brain: involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of α-synuclein. J Pineal Res. 2007;43:163–171.
213. Zhao H, Wu QQ, Cao LF, et al. Melatonin inhibits endoplasmic reticulum stress and epithelial-mesenchymal transition during bleomycin-induced pulmonary fibrosis in mice. PLoS ONE. 2014;9:e97266.
214. Ji YL, Wang H, Meng C, et al. Melatonin alleviates cadmium-induced cellular stress and germ cell apoptosis in testes. J Pineal Res. 2012;52:71–79.
215. Sharma S, Sarkar J, Haldar C, et al. Melatonin reverses Fas, E2F-1 and endoplasmic reticulum stress mediated apoptosis and dysregulation of autophagy induced by the herbicide atrazine in murine splenocytes. PLoS ONE. 2014;9:e108602.
216. Carloni S, Albertini MC, Galluzzi L, et al. Melatonin reduces endoplasmic reticulum stress and preserves sirtuin 1 expression in neuronal cells of newborn rats after hypoxia–ischemia. J Pineal Res. 2014;57:192–199.
217. Wang H, Li L, Zhao M, et al. Melatonin alleviates lipopolysaccharide-induced placental cellular stress response in mice. J Pineal Res. 2011;50:418–426.
218. Lim HD, Kim YS, Ko SH, et al. Cytoprotective and anti-inflammatory effects of melatonin in hydrogen peroxide-stimulated CHON-001 human chondrocyte cell line and rabbit model of osteoarthritis via the SIRT1 pathway. J Pineal Res. 2012;53:225–237.
219. Pei M, He F, Wei L, et al. Melatonin enhances cartilage matrix synthesis by porcine articular chondrocytes. J Pineal Res. 2009;46:181–187.
220. Liu X, Xu Y, Chen S, et al. Rescue of proinflammatory cytokine-inhibited chondrogenesis by the antiarthritic effect of melatonin in synovium mesenchymal stem cells via suppression of reactive oxygen species and matrix metalloproteinases. Free Radic Biol Med. 2014;68:234–246.
221. Hong Y, Kim H, Lee Y, et al. Salutary effects of melatonin combined with treadmill exercise on cartilage damage. J Pineal Res. 2014;57:53–66.